Pathos AI lands $365 million for AI-driven cancer drugs

Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a series D financing round, lifting its valuation to about $1.6 billion. The company, based in Boston, plans to use the funds to advance its clinical-stage pipeline and further develop its proprietary AI foundation model for oncology.

The latest round comes just seven months after Pathos secured $62 million in series C funding, bringing its total capital raised to roughly $467 million. The company did not disclose the investors behind the new round.

Chief executive Iker Huerga, who took the helm earlier this month after leading oncology data science at AstraZeneca (LSE AZN), said the financing will help Pathos build “one of the most advanced AI engines” in the sector. Mr Huerga explained that the company’s goal is to “accelerate development, deepen clinical insight, and ensure the right therapies reach the patients who need them most.”